Commercialization challenges associated with induced pluripotent stem cell-based products

Regenerative Medicine
Devyn Smith

Abstract

Induced pluripotent stem (iPS) cells have generated excitement in the regenerative medicine industry. Products derived from iPS cells could be used in a range of drug discovery and development processes. These nontherapeutic products will continue to be launched over the next 5 years, and provide income and knowledge to drive the therapeutic use of iPS cells forward. While the commercial opportunity for iPS cell-based therapies is potentially large, the looming technical and scientific hurdles must be overcome and, thus, the launch of a therapy based on iPS cells is unlikely to occur until the 2020s. While the launch of a therapeutic is many years away, the business models for commercialization should be well understood and proven based on experience with other non-iPS cell-based therapies (both autologous and allogeneic) that will already be on the market.

References

Aug 2, 2003·The New England Journal of Medicine·William M Lee
May 1, 2007·Regenerative Medicine·Chris Mason
Jun 8, 2007·Nature·Keisuke OkitaShinya Yamanaka
Jul 8, 2008·Drug Discovery Today·Ralf Kettenhofen, Heribert Bohlen
May 15, 2009·Regenerative Medicine·Chris Mason, Elisa Manzotti
Jun 30, 2009·Biological Chemistry·Alexandra Rolletschek, Anna M Wobus
Jul 8, 2009·Regenerative Medicine·Anke C PlagnolFinbarr Livesey
Nov 10, 2009·Nature Biotechnology·Sarah Webb
Jan 7, 2010·The Journal of Clinical Investigation·Evangelos Kiskinis, Kevin Eggan
Feb 12, 2010·Nature·Monya Baker

❮ Previous
Next ❯

Citations

May 9, 2012·New Biotechnology·Weerapong Prasongchean, Patrizia Ferretti
Dec 19, 2013·BioMed Research International·Constança FigueiredoRainer Blasczyk
Sep 10, 2011·Stem Cells International·Rosario Isasi, Bartha M Knoppers
Oct 21, 2011·Pharmaceuticals·Anna ArnoMarc G Jeschke
Jul 17, 2010·Regenerative Medicine·M William Lensch, Mahendra Rao

❮ Previous
Next ❯

Methods Mentioned

BETA
genetic modifications

Software Mentioned

Cytori Celution System
Catalyst
Ubiquigent
Stemgent
iCell
Cellular Dynamics
ADIS
BioInformant
Insight
ArunA

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.